HOME
ABOUT US
SOCIAL IMPACT
STRATEGY
GENE THERAPY
CELL THERAPY
RNA-BASED THERAPY
TARGETED THERAPIES
MICROBIOME
TEAM
PORTFOLIO
VENTURE PORTFOLIO
PAST PORTFOLIO
4BATLE ICAV
NEWS ROOM
CONTACT
More
Use tab to navigate through the menu items.
NEWS ROOM
Nov 1, 2018
4BIO portfolio company Orchard Therapeutics goes public
Aug 13, 2018
4BIO portfolio company Orchard Therapeutics Announces $150 Million Series C Financing
Apr 13, 2018
GSK Hands Off Rare Disease Gene Therapy Portfolio to Orchard Therapeutics
Mar 24, 2018
TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval
Jan 5, 2018
Takeda announces its intention to acquire TiGenix
Jan 3, 2018
Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs
1
2
3
4
ARCHIVE
June 2022
April 2022
March 2022
February 2022
January 2022
December 2021
October 2021
April 2021
March 2021
January 2021
December 2020
November 2020
October 2020
July 2020
June 2020
May 2020
March 2020
November 2019
September 2019
February 2019
SEARCH BY TAGS
portfolio
4BIO Ventures II
investment
Orchard Therapeutics
appointment
approval
collaboration
advisory board
CodeBio
SparingVision
Spark Therapeutics
Takeda
AAV
acquisition
ADC Therapeutics
IPO
publication
Ray Therapeutics
review
TiGenix
4BATLE
AI
awards
BLA
Carisma
clinical trials
EGLS
ETF
grant
Harbor Capital
Insig AI
Intellia
Kyowa Kirin
Luca Science
Moderna
pricing
Redpin Therapeutics
results
venture
FOLLOW US
